Literature DB >> 24297455

Multilevel Factors Associated With Overall Mortality for Men Diagnosed With Prostate Cancer in Florida.

Hong Xiao1, Fei Tan2, Pierre Goovaerts3, Askal Ali4, Georges Adunlin4, Clement K Gwede5, Youjie Huang6.   

Abstract

To identify individual and contextual factors contributing to overall mortality among men diagnosed with prostate cancer in Florida, a random sample of patients (between October 1, 2001, and December 31, 2007) was taken from the Florida Cancer Data System. Patient's demographic and clinical information were obtained from the Florida Cancer Data System. Comorbidity was computed following the Elixhauser Index method. Census-tract-level socioeconomic status and farm house presence were extracted from Census 2000 and linked to patient data. The ratio of urologists and radiation oncologists to prostate cancer cases at the county level was computed. Multilevel logistic regression was conducted to identify significance of individuals and contextual factors in relation to overall mortality. A total of 18,042 patients were identified, among whom 2,363 died. No racial difference was found in our study. Being older at diagnosis, unmarried, current smoker, uninsured, diagnosed at late stage, with undifferentiated, poorly differentiated, or unknown tumor grade were significantly associated with higher odds of overall mortality. Living in a low-income area was significantly associated with higher odds of mortality (p = .0404). After adjusting for age, stage, and tumor grade, patients who received hormonal, combination of radiation with hormone therapy, and no definitive treatment had higher odds of mortality compared with those who underwent surgery only. A large number of comorbidities were associated with higher odds of mortality. Although disease-specific mortality was not examined, our findings suggest the importance of careful considerations of patient sociodemographic characteristics and their coexisting conditions in treatment decision making, which in turn affects mortality.
© The Author(s) 2013.

Entities:  

Keywords:  comorbidity; diagnosis; mortality; multilevel; prostate cancer

Mesh:

Year:  2013        PMID: 24297455      PMCID: PMC4040343          DOI: 10.1177/1557988313512862

Source DB:  PubMed          Journal:  Am J Mens Health        ISSN: 1557-9883


  70 in total

1.  Prostate cancer in the elderly: frequency of advanced disease at presentation and disease-specific mortality.

Authors:  Emil Scosyrev; Edward M Messing; Supriya Mohile; Dragan Golijanin; Guan Wu
Journal:  Cancer       Date:  2011-10-17       Impact factor: 6.860

2.  Explaining racial differences in prostate cancer mortality.

Authors:  Glen B Taksler; Nancy L Keating; David M Cutler
Journal:  Cancer       Date:  2012-01-13       Impact factor: 6.860

3.  Smoking and risk of total and fatal prostate cancer in United States health professionals.

Authors:  E Giovannucci; E B Rimm; A Ascherio; G A Colditz; D Spiegelman; M J Stampfer; W C Willett
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1999-04       Impact factor: 4.254

4.  Geographic variation across veterans affairs medical centers in the treatment of early stage prostate cancer.

Authors:  Benjamin A Spencer; Constance H Fung; Mingming Wang; Lisa V Rubenstein; Mark S Litwin
Journal:  J Urol       Date:  2004-12       Impact factor: 7.450

Review 5.  The impact of age and comorbidity on survival outcomes and treatment patterns in prostate cancer.

Authors:  W H Hall; A B Jani; J K Ryu; S Narayan; S Vijayakumar
Journal:  Prostate Cancer Prostatic Dis       Date:  2005       Impact factor: 5.554

6.  20-year outcomes following conservative management of clinically localized prostate cancer.

Authors:  Peter C Albertsen; James A Hanley; Judith Fine
Journal:  JAMA       Date:  2005-05-04       Impact factor: 56.272

Review 7.  Active surveillance for prostate cancer: a systematic review of the literature.

Authors:  Marc A Dall'Era; Peter C Albertsen; Christopher Bangma; Peter R Carroll; H Ballentine Carter; Matthew R Cooperberg; Stephen J Freedland; Laurence H Klotz; Christopher Parker; Mark S Soloway
Journal:  Eur Urol       Date:  2012-06-07       Impact factor: 20.096

8.  Outcome following active surveillance of men with screen-detected prostate cancer. Results from the Göteborg randomised population-based prostate cancer screening trial.

Authors:  Rebecka Arnsrud Godtman; Erik Holmberg; Ali Khatami; Johan Stranne; Jonas Hugosson
Journal:  Eur Urol       Date:  2012-09-05       Impact factor: 20.096

9.  Construction of a comorbidity index for prostate cancer patients linking state cancer registry with inpatient and outpatient data.

Authors:  Hong Xiao; Fei Tan; Pierre Goovaerts; Askal Ali; Georges Adunlin; Youjie Huang; Clement Gwede
Journal:  J Registry Manag       Date:  2013

10.  Use of treatment information from a state central cancer registry in prostate cancer research.

Authors:  Hong Xiao; Fei Tan; Pierre Goovaerts; Georges Adunlin; Askal Ayalew Ali; Clement K Gwede; Youjie Huang
Journal:  J Registry Manag       Date:  2013
View more
  2 in total

Review 1.  Combining Nonclinical Determinants of Health and Clinical Data for Research and Evaluation: Rapid Review.

Authors:  Elizabeth Golembiewski; Katie S Allen; Amber M Blackmon; Rachel J Hinrichs; Joshua R Vest
Journal:  JMIR Public Health Surveill       Date:  2019-10-07

2.  Risk factors involved in treatment delays and differences in treatment type for patients with prostate cancer by risk category in an academic safety net hospital.

Authors:  Carolyn K Kan; Muhammad M Qureshi; Apar Gupta; Ankit Agarwal; Gretchen A Gignac; B Nicolas Bloch; Nicholas Thoreson; Ariel E Hirsch
Journal:  Adv Radiat Oncol       Date:  2017-12-13
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.